by Francisca Peixoto | Mar 18, 2021 | Uncategorized
For our latest newsletter we have compiled a summary of the efficacy and side effects for the first generation of Covid-19 vaccines. We aim to provide a reliable source of biotechnological information for the public. To access the full document please click here:...
by feryadmin | Jan 20, 2021 | Uncategorized
Accure Therapeutics, one of our portfolio companies, is starting 2021 strong by incorporating five neurology world-class experts into their scientific advisory board. #neurology #clinicalstudies #brain #opticneuritis #parkinsonsdisease #multiplesclerosis...
by feryadmin | Dec 10, 2020 | Uncategorized
Join us today at 4:50pm CET for a session about “Life Sciences for Impactful Transition” at the Nordic Impact Business Summit. Full day streaming (open to anyone): https://lnkd.in/eCvyH6M Moderated by: Frederik van Deurs, CEO, Green Innovation Group [DK] Guests...
by feryadmin | Nov 9, 2020 | Uncategorized
Eveliqure Biotechnologies GmbH today announces the award of a US government contract from the National Institute of Allergy and Infectious Diseases (NIAID), contract #75N93020C00048 with the intent to fund the development of its vaccine candidate, ShigETEC, through...
by feryadmin | Nov 9, 2020 | Uncategorized
Extremely interesting interview with Dr. Jennifer Doudna, co-developer of the groundbreaking gene editing technology and Nobel Prizer winner in Chemistry this year together with Dr. Emmanuelle Charpentier. During this interview, Dr. Doudna talks in a very clear way...
by feryadmin | Sep 9, 2020 | Uncategorized
Calyxha Biotechnologies GmbH is developing novel therapies targeting #neurodegeneration, the underlying cause of major human diseases, such as Parkinson’s disease. https://www.calyxha.com/
